Lawson obtains $4.4mn for adverse drug reaction prevention program
Date: 2018-02-27   Author: Dhananjay Punekar  Category: #news

Lawson Health Research Institute, a London-headquartered hospital-based research institute, is likely to receive USD 4.4 million in the form of investments for conducting research on preventing adverse drug reactions. According to some of the key officials of the institute, adverse medicine reactions incur an expenditure of more than USD 5 billion per year for the healthcare sector in Canada. They further claimed that drug reactions are one of the leading causes of patient deaths in hospitals as well.

The institute states that over the past few years, biotechnology has made rapid advances where one can get results of DNA analysis on the same-day after conducting clinical trials. From the outcomes, doctors are now able to forecast whether a patient requires a high or low dose of a particular medicine.

Reportedly, researchers are of the view that genetic markers have proved beneficial not only for doctors but have also helped in saving the lives of numerous patients. As per reliable sources, the Ontario Research Fund, London Health Sciences Foundation, and Thermo Fisher Scientific have been providing funds to Lawson for each quarter of the year commencing from 2017. The funding is apparently expected to continue till next five years.

The head of the research group at Lawson has announced that the research & development study on adverse drug reactions will help in the expansion of its personalized medicine project over the next few years. The funding also aims to promote the application of personalized drugs in the pharmaceutical, biotechnology & healthcare sectors, as these medicines make use of the patient’s DNA to determine the effects of particular drugs on the patient’s immune system, skin, and other internal & external parts of the body.

For the record, the funding that Lawson’s research team has received will also be used to test many other drugs. It is being speculated that the investments have facilitated the institute to prescribe 5-fluorouracil for conducting clinical trials on cancer patients.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Apple & Volkswagen join hands to manufacture self-driving vans
Author: Saif Ali Bepari

Apple has apparently teamed up with the German automotive giant Volkswagen to manufacture self-driving vehicles that would ferry employees across its campuses. As per reliable sources, the latest collaboration would pr...


Tesco Plc bans non-recyclable packaging for its own products
Author: Dhananjay Punekar

Tesco Plc, a UK based grocery & general merchandise retailer, has decided to impose a ban on all non-recyclable packaging on its own products. The decision is apparently aimed at reducing the proportion of plastic ...


JetBlue-backed Zunum planning to bet big on hybrid-to-electric planes
Author: Sunil Hebbalkar

The United States based JetBlue Airways is reportedly lending support to a private hybrid plane manufacturing start-up called Zunum. As per reliable sources, Zunum is looking forward to launching fully electric planes ...